Log in
NASDAQ:EYEG

Eyegate Pharmaceuticals Stock Forecast, Price & News

$3.82
+0.09 (+2.41 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.75
Now: $3.82
$3.95
50-Day Range
$3.60
MA: $3.81
$4.06
52-Week Range
$2.85
Now: $3.82
$12.89
Volume17,393 shs
Average Volume107,894 shs
Market Capitalization$17.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Read More
Eyegate Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-8869
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.69 million
Book Value$1.64 per share

Profitability

Net Income$-7,100,000.00

Miscellaneous

Market Cap$17.68 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$3.82
+0.09 (+2.41 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

How has Eyegate Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eyegate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EYEG shares have decreased by 24.1% and is now trading at $3.82.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Eyegate Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eyegate Pharmaceuticals
.

When is Eyegate Pharmaceuticals' next earnings date?

Eyegate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Eyegate Pharmaceuticals
.

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.05.
View Eyegate Pharmaceuticals' earnings history
.

What price target have analysts set for EYEG?

2 Wall Street analysts have issued twelve-month target prices for Eyegate Pharmaceuticals' shares. Their forecasts range from $9.50 to $12.00. On average, they anticipate Eyegate Pharmaceuticals' share price to reach $10.75 in the next twelve months. This suggests a possible upside of 181.4% from the stock's current price.
View analysts' price targets for Eyegate Pharmaceuticals
.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totaling 27,000 shares, a decrease of 18.7% from the August 31st total of 33,200 shares. Based on an average daily trading volume, of 201,500 shares, the short-interest ratio is presently 0.1 days. Approximately 0.6% of the company's shares are short sold.
View Eyegate Pharmaceuticals' Short Interest
.

Who are some of Eyegate Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyegate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Novavax (NVAX), SCYNEXIS (SCYX), Trevena (TRVN), Exelixis (EXEL) and Gilead Sciences (GILD).

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the following people:
  • Mr. Stephen From, Pres, CEO & Director (Age 56)
  • Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
  • Mr. Michael P. Manzo, VP of Engineering (Age 60)
  • Ms. Sarah Romano, Chief Financial Officer
  • Dr. MaryJane Rafii Ph.D., Consultant

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $3.82.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $17.68 million and generates $2.69 million in revenue each year. The specialty pharmaceutical company earns $-7,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.

What is Eyegate Pharmaceuticals' official website?

The official website for Eyegate Pharmaceuticals is www.eyegatepharma.com.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.